Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AV-45 (Florbetapir 18F) Amyloid PET Imaging in Primary Progressive Aphasia
2010-023852-10Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Aug 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Florbetapir in primary progressive aphasia (PPA) and Alzheimer's disease (AD) (3 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Primary amyloid uptake assessment. Started Aug 2011; status: completed.
02
Drugs
Florbetapir
03
Conditions
primary progressive aphasia (PPA)Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-023852-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023852-10.